NCT06423326View on ClinicalTrials.gov

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Borderline Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic AdenocarcinomaStage I Pancreatic Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cisplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Gemcitabine

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Nab-paclitaxel

Given IV

PROCEDURE

Pancreatic Surgical Procedure

Undergo surgical resection

Trial Locations (1)

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER